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A   adenine 
aa   amino acid 
ACTH   adrenocorticotrophin  
AIP    aryl hydrocarbon receptor-interacting protein 
AHR     aryl hydrocarbon receptor 
ALK     anaplastic lymphoma kinase  
ARA9   aryl hydrocarbon receptor-associated protein-9 (or AIP, XAP2) 
ARNT    aryl hydrocarbon receptor nuclear translocator 
bp   base pair 
BIRC5    baculoviral IAP repeat-containing 5 (survivin) 
BRCA1   breast and ovarian cancer 1  
BRCA2   breast and ovarian cancer 2  
C   cytosine 
CNC    Carney complex 
cAMP   cyclic adenosine monophosphate 
CDK4    cyclin-dependent kinase 4 
CDKN1B/p27Kip1 cyclin-dependent kinase inhibitor 1B 
DNA    deoxyribonucleic acid 
EBNA3  Epstein-Barr virus (EBV) nuclear antigen-3 
FH     fumarate hydratase 
FIPA   familial isolated pituitary adenomas 
FKBP    FK506 binding protein 
FSH    follicle-stimulating hormone 
G   guanine 
GADD45    growth arrest and DNA-damage-inducible gamma 
GH     growth hormone 
GNAS    guanine nucleotide-binding protein, alpha stimulating activity 
polypeptide 
Gs     guanosine triphosphate-binding protein 
GTP    guanosine triphosphate 
HIF1-    hypoxia inducible factor 1, alpha subunit 
HNPCC  hereditary non-polyposis colorectal cancer 
HSP90   heat-shock protein 90 
IFS    isolated familial somatotropinoma 
IGF-I    insulin-like growth factor 1 
IHC    immunohistochemistry 
KIT     v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene 
homolog 
LH    luteinizing hormone 
LOH    loss of heterozygocity 
MAS    McCune-Albright syndrome 
MEN1    multiple endocrine neoplasia type 1 
MEN4    multiple endocrine neoplasia type 4 
MET     met proto-oncogene (hepatocyte growth factor receptor) 
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MIM    Mendelian Inheritance in Man 
MLH1    MutL E.coli homologue 1 
MSH2    MutS E.coli homologue 2 
MRI    magnetic resonance imaging 
NFPA    non-functioning pituitary adenoma 
NMTC   non-medullary thyroid cancer 
PAP   pituitary adenoma predisposition 
PCR    polymerase chain reaction 
PDE2A  phosphodiesterase 2 A 
PDE4A5  phosphodiesterase 4 A5 
PKA   protein kinase A 
PPAR-     peroxisome proliferation-activated receptor alfa 
PPNAD   pigmented nodular adrenocortical disease 
PRKAR1A  protein kinase A (PKA) regulatory subunit 1 alfa  
PRL    prolactin 
PTC    parathyroid cancer 
ptg-FGFR4  pituitary tumor-derived fibrolast growth factor receptor 4 
RET     rearranged during transfection proto-oncogene 
SNP    single nucleotide polymorphism 
T   thymine 
THR 1   thyroid receptor beta 1 
TOMM20  translocase of the outer membrane of mitochondria 20 
TPR     tetratricopeptide repeat 
TSH    thyrothophin-releasing hormone 
XAP2    hepatitis B virus x-associated protein 2 (or AIP,ARA9) 
 
 





Identification of genes predisposing to tumor syndromes has raised general 
awareness of tumorigenesis. Genetic testing of tumor susceptibility genes aids the 
recognition of individuals at increased risk of tumors. Identification of novel 
predisposing genes enables further studies concerning the classification of 
potential associated tumors and the definition of target patient group. 
 
Pituitary adenomas are common, benign neoplasms accounting for 
approximately 15% of all intracranial tumors. Accurate incidence estimation is 
challenging since a great portion of these adenomas are small and asymptomatic. 
Clinically relevant adenomas, that cause symptoms due to the expansion of the 
cell mass or the over-secretion of normally produced hormones, occur in  
approximately one of 1 000 individuals. Although the majority of pituitary 
adenomas are sporadic, a minority occur as components of familial syndromes, 
such as Multiple Endocrine Neoplasia type 1 (MEN1) and Carney complex 
(CNC). MEN1 syndrome is caused by germ-line mutations in the MEN1 gene, 
whereas most of the CNC patients carry the mutated protein kinase A (PKA) 
regulatory subunit-1-  (PRKAR1A) gene.  
 
Recently, other conditions predisposing to endocrine tumors have been 
identified: Pituitary Adenoma Predisposition (PAP) and MEN type 4 (MEN4). 
PAP was originally identified in a genetically homogeneous Finnish population. 
In a population based cohort from Northern Finland, aryl hydrocarbon receptor-
interacting protein (AIP) gene mutations were found in 16% of all patients 
diagnosed with growth hormone (GH) producing pituitary adenoma, and in 40% 
of the subset of patients who were diagnosed under the age of 35 years.  
 
Since AIP mutations were originally described in a defined, homogeneous 
population from Northern Finland, it was relevant to study whether mutations 
also occur in more heterogeneous populations. In patient cohorts with different 
ethnic origins and variable clinical phenotypes, germ-line AIP mutations were 
detectable at low frequencies (range 0.8-7.4%).  AIP mutation-positive patients 
were often diagnosed with a GH-producing adenoma at a young age, and 
usually had no family history of endocrine tumors. The low frequency of AIP 
mutations in randomly selected patients, and the lack of any family history of 
pituitary adenomas create a challenge for the identification of PAP patients. Our 
preliminary study suggests that AIP immunohistochemistry may serve as a pre-
screening tool to distinguish between the AIP mutation-negative and the 
mutation-positive tumors. 
 
Tumors of various endocrine glands are components of MEN1 and CNC 
syndromes. Somatic MEN1 and PRKAR1A mutations in sporadic pituitary 
adenomas are rare, but occur in some of the other tumors related to these 
syndromes. The role of AIP mutations in endocrine neoplasia was studied and 
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our results indicated that somatic AIP mutations are rare or non-existent in 
sporadic tumors of endocrine glands (0 of 111). Furthermore, germ-line AIP 
mutations in prolactin producing adenomas (2 of 9) confirmed the role of this 
pituitary tumor type in the PAP phenotype.  
 
Thyroid disorders are common in the general population, and the majority of 
them are sporadic. Interestingly, it has been suggested that thyroid disorders 
might be more common in PAP families. For this reason we studied germ-line 
AIP mutations in 93 index cases from familial non-medullary thyroid cancer 
(NMTC) families. The underlying gene or genes for familial NMTC have not been 
identified yet. None of the patients had any potentially pathogenic AIP mutation. 
This suggests that AIP is unlikely to play a role in familial NMTCs. 
 
A novel multiple endocrine syndrome was originally described in rats with 
phenotypic features of human MEN type 1 and 2. Germ-line mutations of cyclin-
dependent kinase inhibitor 1B (CDKN1B also known as p27Kip1) gene were reported 
later in these rats and a germ-line mutation was also identified in one human 
family with MEN1-like phenotype (later named MEN4). To confirm the 
importance of this gene’s mutations in humans, we performed a mutation 
screening in MEN-like patients and in patients with pituitary adenoma. Our 
results indicate that CDKN1B/p27Kip1 mutations appear in a small portion of 
MEN1-like patients (one of 36), and that such mutations are rare or non-existent 
in both familial (0 of 19) and sporadic pituitary adenoma patients (0 of 50). 
 
In conclusion, this work strengthens the tumor susceptibility role of AIP and 
CDKN1B/p27Kip1 in endocrine neoplasia. Clarifying the PAP phenotype facilitates 
the identification of potential AIP mutation carriers. Genetic counseling can be 
offered to the relatives and follow-up of the mutation carriers can be organized, 







Tumors arise from normal tissue when a cell transforms into a malfunctioning 
one. The growth advantage of the cell is achieved by accumulation of genetic 
alterations. Variety of environmental and lifestyle factors can affect tumor 
formation due to their ability to mutate genes. These factors correlate with the 
incidence of certain cancers such as exposure to ultraviolet radiation with skin 
cancer, tobacco smoking with lung cancer, and inadequate diet with stomach 
cancer (Weinberg 2007).  
 
An individual with an inherited mutation in a crucial gene is predisposed to 
tumor formation at a higher risk than the general population. However, a single 
mutated gene alone is seldom sufficient to trigger tumor formation but does 
contribute to it. For example, it has been estimated that 15 mutations are involved 
in the initiation, progression, and maintenance of colorectal and breast cancer 
(Wood et  al. 2007). Approximately 1.5% of human genome carries the sequence 
information that encodes the structures of protein and occurrence of somatic 
mutations in human tissues is estimated to be less than 10-8 per base pair (Bielas 
et al. 2006; Weinberg 2007). Thus, sporadic tumor formation is a slow process. 
Mutation patterns vary between different tumor types but all of them display 
features uncommon to normal cells. These include self-sufficiency in growth 
signals, insensitivity to growth-inhibitory signals, evasion of apoptosis, limitless 
replication potential, sustained angiogenesis, and the capability of invasion and 
metastasis (Hanahan and Weinberg 2000). 
 
Tumors can be divided into two categories according to their growth pattern. 
Benign tumors grow locally without invading adjacent tissues, whereas 
malignant tumors are able to invade and send metastases. The majority of the 
primary tumors are actually benign and thus cause no symptoms. In rare cases, 
however, the over-secretion of hormones and/or excessive tumor expansion 
causing pressure on the adjacent tissues, lead to clinical symptoms. For example 
growth hormone (GH) producing pituitary adenomas lead to acromegaly. Even 
though benign tumors only rarely cause deaths, those tumors can be clinically 
important. 
 
This work focuses on endocrine neoplasia caused by mutations in two genes, aryl 
hydrocarbon receptor-interacting protein (AIP) and cyclin-dependent kinase inhibitor 1B 
(CDKN1B also known as p27Kip1). Both genes predispose to pituitary adenomas 
and the latter gene also to other endocrine tumors. The contribution of these 
genes to tumorigenesis in endocrine neoplasia is not completely clarified. This 




2. REVIEW OF THE LITERATURE 
2.1. Tumor genes 
 
As mentioned above, the transformation from a normal cell to a tumor lesion 
requires several cellular events. These include mutations in the genome leading 
to loss of function of tumor suppressor genes or to gain of function of oncogenes.  
2.1.1. Tumor suppressor genes 
 
Tumor suppressor genes can be divided into three groups according to their role 
in cellular processes: gatekeepers, landscapers, and caretakers (Kinzler and 
Vogelstein 1997; Kinzler and Vogelstein 1998). Inhibitors of the cell cycle 
progression and promoters of the apoptosis of abnormal cells are called 
gatekeepers. Landscaper genes are involved in the cellular microenvironment 
(stromal cells). Caretaker genes repair DNA errors and therefore mutations in 
these genes leads to the accumulation of alterations in the genome (Kinzler and 
Vogelstein 1997; Kinzler and Vogelstein 1998). 
 
Tumor suppressor genes are mainly inactivated when the activity of both alleles 
is lost (Knudson’s two hit hypothesis) (Knudson 1971).  In heritable neoplastic 
syndromes the “first hit” is in the germ-line and the “second hit” occurs 
somatically to the wild-type allele. Often the inherited mutation is small, such as 
a point mutation or a small deletion/insertion, and the somatically occurring one 
is larger, such as loss of a particular chromosomal area. Loss of the tumor 
suppressor function may also be due to haploinsufficiency or dominant-negative 
effect when only a single allele inactivation is enough to promote tumorigenesis 
(Payne and Kemp 2005). 
 
Predisposing mutations in tumor suppressor genes have been identified in 
several well known syndromes. These genes include BRCA1 and BRCA2 in 
hereditary breast and ovarian cancer (Futreal et al. 1994; Miki et al. 1994; Wooster 
et al. 1995), MEN1 in multiple endocrine neoplasia type 1 (MEN1) 
(Chandrasekharappa et al. 1997), FH mutations in hereditary leiomyomatosis and 
renal cell cancer (Tomlinson et  al. 2002), and mismatch-repair genes (e.g. MLH1 
and MSH2) in hereditary nonpolyposis colorectal cancer (HNPCC) (Bronner et al. 





Oncogenes are abnormally activated normal genes, called proto-oncogenes. 
These normal genes are involved in several cellular processes, such as cell 
proliferation, differentiation, and apoptosis. Oncogene activation is achieved by 
activating point mutations in the proto-oncogene, chromosomal translocations, or 
gene amplifications. This leads to either increased expression of the normal 
protein or to aberrant activation of the gene in unfamiliar conditions. Activating 
point mutations and translocations are normally initiating events in the tumor 
formation or occur during tumor progression, whereas amplifications mainly 
occur later in tumorigenesis (Croce 2008).  
 
Inherited oncogene mutations are rare but some have been identified such as RET 
in multiple endocrine neoplasia type 2 (Mulligan et al. 1993), MET in hereditary 
papillary renal cell carcinoma (Schmidt et al. 1997), KIT in familial gastrointestinal 
stromal tumors (Nishida et al. 1998), CDK4 in familial malignant melanoma (Zuo 
et al. 1996), and ALK in familial neuroblastoma (Mosse et al. 2008). 
2.2. Endocrine system 
 
Major endocrine glands consist of pituitary, pineal, thyroid, parathyroids, 
adrenals, endocrine pancreas, thymus, testes (males), and ovaries (female) (Fig. 
1). These tissues release signaling molecules, known as hormones, mainly into the 
bloodstream to affect the functions of the target tissues such as growth, 
development, and metabolism. Through the bloodstream the hormones can be 
circulated to every part of the body. This is called endocrine signaling. Some 
hormones are secreted straight from the neural cells to the endocrine gland 
(neuroendocrine signaling), for example the hypothalamus secretes hormones 
that regulate the function of the anterior pituitary gland. The target of hormones 
can also be the cells nearby (paracrine signaling), the cell’s own receptors in the 
outer membrane (autocrine signaling) or the cell’s own receptors in the nucleus 






Figure 1. Major endocrine glands (modified from the website www.ama-
assn.org). 
 
Cooperation of the endocrine systems is composed of feedback mechanisms in 
both hormonal and neural communication networks. Positive and negative 
feedback control the hormone secretion. For instance, releasing and inhibiting 
factors secreted by the hypothalamus affect the function of the pituitary gland 
(Fig. 2). The pituitary hormones induce the hormone secretion of target organs 
and tissues. These peripheral hormones inhibit the hormone secretion of the 
hypothalamus and the pituitary gland. Also, para- and autocrine signaling are 






Figure 2. Diagram of the feedback control in the hypothalamic-pituitary-target 
tissue axis. Secretion of the pituitary hormone-releasing hormone induces the 
target tissue-stimulating hormone secretion from the pituitary gland. Pituitary 
hormones stimulate the synthesis and release of the hormones from the target 
tissue. Inhibition of the hormone secretion is achieved by negative feedback from 
the target tissues to the pituitary gland and the hypothalamus. Also autocrine 
and paracrine signaling affect the function of the pituitary gland and the 
hypothalamus. Stimulation is indicated by a plus sign, whereas inhibition is by a 
minus sign. The direction of the feedback is indicated by arrows. (Valimaki et al. 
2009)  
 
In this study, pituitary adenomas relate to both of the studied genes (AIP and 
CDKN1B/p27Kip1) and therefore pituitary gland (section 2.2.1.) and its adenomas 
(section 2.3.1.) are introduced in more details. 
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2.2.1. The pituitary gland 
 
The pituitary gland is located behind the eyes, at the base of the brain, and on top 
of the sphenoid bone (Fig. 1). The gland is a bean-shaped tissue and it is divided 
into the anterior and the posterior lobes (Fig. 3). Hypothalamic antidiuretic 
hormone (arginine vasopressin) and oxytocin are stored and secreted to the 
blood-stream from the posterior lobe when needed. Six different pituitary 
hormones are produced and released from the anterior lobe (Fig. 3, Table 1). 
These pituitary hormones regulate growth and development in general and as 
well as the function of three other endocrine glands: the thyroid, the adrenals, 





Figure 3. A schematic presentation of the pituitary gland, the secreted hormones, 
and the target tissues of the hormones. 
2.3. Endocrine neoplasia  
 
Neoplasias of the endocrine system are normally benign. Even thought 
malignancies are rare, thyroid cancers are the most common type, accounting for 
1% of all cancers in the developed countries (Steward and Kleihues 2003).  
Tumors are prevalent in some endocrine tissues such as in the pituitary and 
thyroid glands. However, adrenal and pancreatic endocrine tumors are rare 
(DeLellis et al. 2004). Most of the endocrine tumors are sporadic but some arise as 
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components of familial syndromes such as multiple endocrine neoplasias, and 
Carney complex (introduced in section 2.4. below). 
 
Clinical symptoms can vary in different endocrine disorders according to 
hormone activity. Decreased or lack of hormone synthesis can be due to a 
missing endocrine gland, dysfunction of hormone synthesis or destruction of the 
endocrine gland e.g. after infection or radiation. A defective response to 
hormones can be due to the incorrect structure of the hormone or malfunction of 
the receptor. Increased hormone synthesis is a consequence of a hyperplasia, a 
tumor or extra stimulation of the endocrine gland. (Valimaki et al. 2009) 
 
Table 1. The pituitary hormones secreted by the anterior lobe. The target tissues 
and functions are also presented (Valimaki et al. 2009). 
 




Mammary glands Initiation and maintenance of milk 
production 
Growth hormone (GH) Liver and other tissues Metabolic and anabolic effects, growth 
stimulation, and induction of 
particularly hepatic IGF-I production 










Thyroid gland Stimulation of thyroid hormone (T3 
and T4) production 
   
Follicle stimulating 
hormone (FSH) and 
luteinizing hormone (LH) 
Gonads (ovaries and 
testis) 
Germ cell development and 
stimulation of sex steroid hormone 
production 
2.3.1. Pituitary adenomas 
 
Tumors, mostly benign, arise mainly from the anterior lobe of the gland. These 
adenomas are common accounting for ~15% of all intracranial tumors (Karhu and 
Aaltonen 2007). Hormonally inactive, small tumors with a slow growth rate do 
not necessarily cause symptoms, and therefore those are not detected until 
radiographic examination or post-mortem examination. In autopsy studies and in 
radiological imaging done for other indications, the prevalence of incidentally 
discovered pituitary adenomas is estimated to be 5-20% (Burrow et al. 1981; Hall 
et al. 1994; Molitch and Russell 1990). This was supported recently by a meta-
analysis where pituitary adenomas were reported to occur with a frequency of 
16.7% (Ezzat et al. 2004).  
 
The majority of the clinically relevant adenomas produce hormones excessively, 
which can affect many organ systems, thus causing severe symptoms or even 
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death. In addition to the over-secretion of hormones, the expansion of the tumor 
mass causes symptoms, such as headache, and visual-field disturbance. 
Furthermore, tumor compression of the normal pituitary tissue can lead to loss of 
normal hormone production i.e. hypopituitarism (Arafah and Nasrallah 2001). 
These clinically relevant adenomas are rare, but more common than previously 
estimated, as indicated by recent cross-sectional study conducted in Belgium 
(1/1064 population) and an international study (average 0.75/1000 population) 
(Daly et al. 2006b; Daly et al. 2007a). 
 
Pituitary adenomas appear to have reversible plasticity, varying from hypoplasia 
to hyperplasia (Melmed 2003). X-chromosome inactivation in human pituitary 
adenomas suggests that these lesions arise from a single pituitary cell that has 
acquired growth advantage due to genetic or epigenetic alterations (Alexander et 
al. 1990; Herman et  al. 1990). According to animal models, long-term pituitary 
hyperplasia predisposes to tumor progression (Asa et al. 1992; Heaney et al. 1999). 
In humans, however, pituitary hyperplasia due to pregnancy or lactation, its 
enlargement due to estrogen administration, or untreated primary 
hypothyroidism does not seem to enhance tumor formation (Coogan et al. 1995; 
Ghannam et al. 1999; Horvath et al. 1999; Kovacs et al. 1994). 
2.3.1.1. Classification of pituitary adenomas 
 
The World Health Organization’s classification of pituitary adenomas is based on 
clinical and biochemical features. These include imaging, operative findings, 
histology, immunocytochemistry, and electron microscopy (Kovacs et al. 1996). 
Adenomas can also be classified according to the size of the tumor where 
microadenomas are equal or less than 10 mm in diameter, macroadenomas 
greater than 10 mm but less than 4 cm, and tumors over 4 cm in diameter are 
giant adenomas (DeLellis et  al. 2004). Classification can also be based on the 
endocrine activity as detailed in the following paragraphs and summarized in 
Table 2. 
 
The majority of the pituitary adenomas over-secrete prolactin (PRL; 40-45%; 
Table 2) (Arafah and Nasrallah 2001). Prevalence of these adenomas, also called 
prolactinomas, is estimated to be 60-100 cases per million and their incidence is 
around 6-10 new cases per million per year (Ciccarelli et  al. 2005; DeLellis et  al. 
2004). Besides symptoms due to the expansion of the tumor mass and variable 
degrees of hypopituitarism, over-secretion of PRL can lead to menstrual 
irregularities (amenorrhea or oligomenorrhea) or lactation (galactorrhea) in 
females, and to sexual impotence or decreased libido in males (DeLellis et  al. 
2004). 
 
The second largest group of pituitary adenomas over-secrete growth hormone 
(GH; 20%; Table 2) (Arafah and Nasrallah 2001). These adenomas, also called 
somatotropinomas, can simultaneously over-secrete PRL. The clinical 
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manifestation depends on the age of occurrence of the adenoma and the time of 
exposure. GH over-secretion during childhood or adolescence, before epiphyseal 
fusion is completed, leads to accelerated linear growth termed “gigantism” 
(Eugster and Pescovitz 1999). Adulthood exposure to high GH-levels causes 
acromegaly with clinical features such as coarse facial features, broadened nose, 
enlarged extremities, obesity, organomegaly, sweating, and nausea (Chanson and 
Salenave 2008; Melmed 2006). Often adenomas causing acromegaly are large and 
therefore headaches and visual disturbances are common symptoms (Laws et al. 
1985). Incidence of acromegaly is estimated to be 3-4 new cases per million per 
year and the prevalence 40-60 cases per million people (Alexander et  al. 1980; 
Bengtsson et  al. 1988; Kauppinen-Makelin et  al. 2005). Morbidity of acromegaly 
depends on the exposure time of high GH and IGF-I levels (GH induces IGF-I 
production which controls linear and organ growth). Furthermore, untreated 
patients face an increased mortality risk caused by e.g. diabetes, cardiovascular or 
cerebrovascular disease (Colao et al. 2004; Erfurth and Hagmar 2005). Due to the 
slow progression and insidious onset of this disease, the diagnosis may take from 
four to more than ten years (Chanson and Salenave 2008).  
 
Adrenocorticotrophin (ACTH) producing adenomas, also known as 
adenocorticotropinomas, account for 10-12% of all pituitary adenomas (Table 2) 
(Arafah and Nasrallah 2001).  These tumors are mostly benign, but they show 
more invasive features than other pituitary adenomas (Arafah and Nasrallah 
2001). ACTH over-secretion causes increased glucocorticoid production i.e. 
hypercortisolism with clinical features of central obesity, hypertension, proximal 
myopathy, striae, hirsutism, easy bruisability, mood changes, poor wound 
healing, menstrual irregularity, osteoporosis, hyperglycemia, increased 
supraclavicular, and dorso-cervical fat pads (Arafah and Nasrallah 2001). This 
clinical manifestation caused by the excess pituitary secretion of ATCH is called 
Cushing’s disease.  
 
Thyrotropin (TSH) producing adenomas, i.e. thyrotropinomas, are rare among 
pituitary adenomas (1-2%; Table 2) (Arafah and Nasrallah 2001). Diagnosis is 
often delayed and tumors tend to be macroadenomas with invasive and 
aggressive nature (DeLellis et  al. 2004). Patients with these adenomas often 
present a goiter and hyperthyroidism but co-secretion of GH and/or PRL can 
occur in a minority of cases leading to acromegaly and/or 
amenorrhea/galactorrhea (Arafah and Nasrallah 2001; Beck-Peccoz et  al. 1996; 




Table 2. Classification of pituitary adenomas according to their hormone activity. 
(modified from Arafah and Nasrallah 2001; DeLellis et al. 2004) 
  








20% Pre-pubertal: unrestrained somatic growth i.e. 
gigantism 
 










10-15% Mass effects causing headaches, visual 





5-10% Mass effects (see gonadotropinomas) 
Thyrotropinomas 
(TSH-producing) 
1-2% Goiter and mild hyperthyroidism  
 
 
Endocrinically silent adenomas are non-functioning pituitary adenomas (NFPA) 
including both gonadotropinomas and null-cell adenomas (Table 2). The majority 
of NFPAs, accounting for 10-15% of all adenomas, are gonadotropinomas 
producing follicle-stimulating hormone (FSH) and/or luteinizing hormone (LH) 
(Arafah and Nasrallah 2001). However, the hormone secretion is mainly minimal 
or inefficient and therefore clinical behavior is due to the tumor mass expansion 
(Samuels and Ridgway 1995; Snyder 1995). Null-cell adenomas are truly 
endocrinically non-functioning and those account for 5-10% of all pituitary 
adenomas (Table 2) (Arafah and Nasrallah 2001). Null-cell adenomas grow 
slowly and their diagnosis is often made in the 6th decade of life (Kontogeorgos et 
al. 1993; Yamada et  al. 1988). Because of the late diagnosis, these adenomas are 
often macroadenomas with cavernous sinus invasion and suprasellar extension 
occasionally reaching to the hypothalamus (DeLellis et al. 2004).  
2.4. Disorders of pituitary adenomas 
2.4.1. Sporadic pituitary adenomas 
 
The majority of the pituitary adenomas (~95%) are sporadic tumors. Microarray 
studies have shown that the gene expression patterns vary, not only between 
pituitary adenomas and normal pituitary, but also between different pituitary 
adenoma subtypes (Fernandez-Ranvier et al. 2008; Moreno et al. 2005; Morris et al. 
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2005; Ruebel et al. 2006). These studies, among other approaches, have indicated 
potential factors in pituitary tumorigenesis such as pituitary tumor-derived 
fibroblast growth factor receptor 4 (ptg-FGFR4) (Ezzat et  al. 2002), growth arrest 
and DNA damage-inducible gamma (GADD45 ) (Zhang et al. 2002), and guanine 
nucleotide-binding protein, alpha stimulating activity polypeptide (GNAS) 
(Vallar et  al. 1987). However, in many cases it is still unclear which of these 
alterations (reviewed in Asa and Ezzat 2005) are involved in the initiation of 
sporadic pituitary adenoma formation, which of them promote the progression of 
the tumor growth or which are bystanders.  
 
GNAS encodes guanosine triphosphate (GTP)-binding protein Gs . This protein 
activates adenylyl cyclase that increases the cellular levels of cyclic adenosine 
monophosphate (cAMP). In sporadic GH-producing adenomas activating 
mutations of GNAS, also known as gsp oncogene, cause constitutive activation of 
Gs , overactivity of adenylyl cyclase, and increased cAMP levels (Vallar et  al. 
1987). Approximately 40% of human GH-producing adenomas carry activating 
mutations in GNAS gene (Lyons et al. 1990). Furthermore, the expression of Gs  
can be high in the GH-producing adenomas without these mutations (Picard et al. 
2007). 
 
McCune-Albright syndrome (MAS; MIM 174800) is a genetic, but not an 
inherited, congenital syndrome due to a post-zygotic somatic mutation in the 
GNAS gene (Schwindinger et al. 1992; Weinstein et al. 1991). These mutations lead 
to over-secretion of hormones in endocrine cells and also to excessive bone 
matrix formation. MAS is characterized by polyostotic fibrous dysplasia, café-au-
lait spots, endocrine abnormalities such as excess of GH and PRL, and in rare 
cases by other tumors.  
2.4.2. Familial pituitary adenomas 
 
Approximately 5% of pituitary adenomas arise as components of familial 
syndromes. These include Multiple Endocrine Neoplasia type 1 (MEN1), 
Carney’s Complex (CNC), and recently identified conditions: Pituitary Adenoma 
Predisposition (PAP) and Multiple Endocrine Neoplasia type 4 (MEN4). These 
familial syndromes and other conditions involving pituitary adenomas are 
described below and summarized in Table 3. 
2.4.2.1 Multiple Endocrine Neoplasia type 1 (MEN1) 
 
MEN1 (MIM131100; Table 3) is an autosomal dominant syndrome characterized 
by a predisposition to different combinations of tumors of the endocrine system. 
These tumors occur most commonly in parathyroids (~95%), pancreatic islet cells 
(~40%), and the anterior pituitary (~30%) (Lemos and Thakker 2008). Less 
common tumors include adrenocortical tumors, angiomyolipomas, foregut 
lipomas, angiofibromas, thyroid adenomas, carcinoids, and spinal cord 
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ependymomas (Chandrasekharappa et al. 1997; Thakker 1998). MEN1 is inherited 
with a high degree of penetrance; <95% of the patients over 40 year of age 
develop clinical manifestations of the syndrome (Bassett et  al. 1998). Clinical 
symptoms are mainly due to hormone over-secretion, and without treatments 
MEN1 tumors are mortal (Lemos and Thakker 2008). Furthermore, relatives of 
MEN1 patients are at 50% risk of developing the disease (Benson et  al. 1987; 
Calender et al. 1995; Marx et al. 1998; Trump et al. 1996).  
 
The predisposing gene for MEN1 locates at 11q13 and codes for a protein called 
“menin” (Chandrasekharappa et  al. 1997; Larsson et  al. 1988). MEN1 gene  is  
comprised of ten exons, and encodes ten transcripts resulting in 555 aa to 615 aa 
long proteins (Ensembl 54). This protein is mainly nuclear and involved in 
transcriptional regulation, genome stability, cell division, and cell cycle control 
(reviewed in Lemos and Thakker 2008). In sporadic pituitary adenomas MEN1 is 
rarely somatically mutated (e.g. Schmidt et al. 1999; Wenbin et al. 1999; Zhuang et 
al. 1997a) and also menin expression is rarely altered (e.g. McCabe et  al. 1999; 
Theodoropoulou et  al. 2004; Wrocklage et  al. 2002). However, somatic MEN1 
mutations are found in other lesions related to this syndrome such as in 
pancreatic islet cell tumors (e.g. insulinomas ~15% and glucagonomas ~60%) 
(Hessman et  al. 1998; Shan et al. 1998; Zhuang et  al. 1997b), lipomas (~30%) 
(Pannett and Thakker 2001; Vortmeyer et al. 1998), and parathyroid tumors (~10-
20%) (e.g. Carling et al. 1998; Farnebo et al. 1998; Heppner et al. 1997).  
 
It has been estimated that 5-10% of MEN1 patients do not carry MEN1 mutations 
in the coding region or adjacent splice sites (Lemos and Thakker 2008). These 
patients, however, might carry predisposing mutations in untranslated regions, 
in the promoter area, or in introns.  It is also possible that they may present 
phenocopies of the disorder or occasionally belong to the multiple endocrine 
neoplasia type 4 (MEN4) (described in section 2.4.2.6.). 
2.4.2.2. Carney Complex (CNC) 
 
CNC (MIM160980; Table 3) is a rare, autosomal dominant, multiple endocrine 
neoplasia syndrome with spotty skin pigmentation, myxomatosis, schwannomas, 
and endocrine tumors (Carney et al. 1985). Endocrine tumors include e.g. 
testicular neoplasm (33% of male patients), pigmented nodular adrenocortical 
disease (PPNAD) (26% of patients), GH- or PRL-producing pituitary adenomas 
(~10%), and thyroid adenoma or carcinoma (5%) (Stratakis et al. 2001). The 
manifestation of CNC can be diverse and occur in different ages. For instance, 
PPNAD or cardiac myxomas are normally seen in the second or third decade of 
life but also already in the first couple of years of life (Boikos and Stratakis 
2007a). Over half of the disease-specific deaths among CNC patients are due to 




More than 60% of the CNC patients that meet diagnostic criteria have mutations 
in protein kinase A (PKA) regulatory subunit-1-  (PRKAR1A) gene (Kirschner et al. 
2000). This gene locates at 17q24 and comprises of 11 exons and three possible 
transcripts each encoding for identical 381 aa long protein (Ensembl 54). PKA, 
also known as cAMP-dependent kinase, is involved in transcription, metabolism, 
cell cycle progression, and apoptosis. Loss of PRKAR1A function leads to 
enhanced intracellular signaling by PKA, thus causing elevated cAMP levels in 
CNC tumors (Kirschner et al. 2000). Somatic PRKAR1A mutations are infrequent 
in sporadic pituitary adenomas (Kaltsas et al. 2002; Sandrini et al. 2002a; Yamasaki 
et al. 2003) and in cardiac myxomas (Fogt et  al. 2002; Mantovani et  al. 2009). 
However, somatic mutations are detected in sporadic PPNAD (three out of five) 
(Groussin et al. 2002), adrenocortical tumors (3/44) (Bertherat et al. 2003), thyroid 
carcinomas (2/17) (Sandrini et  al. 2002b), and odontogenic myxomas (2/21) 
(Perdigao et al. 2005). 
 
Apart from the 17q14 locus, linkage to 2p16 has also been reported but a 
predisposing gene or genes have not been identified (Stratakis et al. 1996). Not all 
the CNC families map to predisposed areas and it is possible that a third so far 
unidentified region exist. 
 
Table 3. Familial pituitary adenoma syndromes.  
 







Neoplasia type 1 
 





adrenal glands, testicles, pituitary 





























Neoplasia type 4 
 
parathyroid glands, pituitary 
gland, kidney b 
12p13 CDKN1B/p27Kip1 
a Only GH-producing adenomas. 
b One family reported. 
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2.4.2.3. Pituitary Adenoma Predisposition (PAP) 
 
PAP is a recently characterized condition with familial pituitary adenomas 
(MIM102200; Table 3) (Vierimaa et  al. 2006). The occurrence of PAP was 
suspected when three small clusters of familial pituitary adenomas were detected 
in Northern Finland. Two of these families were related through common 
ancestor couple born in the 1700s, which was found by additional genealogical 
studies (Vierimaa et al. 2006). The putative predisposing locus at 11q12-13 was 
identified using whole-genome single nucleotide polymorphism (SNP) 
genotyping and narrowed down with fine-mapping (Vierimaa et  al. 2006). 
Previous studies had already suggested that a gene other than than MEN1 in 
11q13 would predispose to GH-producing pituitary adenomas as allelic loss of 
the region had indicated (Gadelha et  al. 1999; Soares et  al. 2005; Thakker et  al. 
1993; Yamada et al. 1997).  
 
With the combined information from linkage data and whole transcriptome 
expression data the primary candidate predisposing gene aryl hydrocarbon 
receptor-interacting protein (AIP) was defined (Vierimaa et al. 2006). And indeed, 
pituitary adenoma clusters detected from Northern Finland harbored a nonsense 
germ-line mutation c.40C>T (p.Gln14X). This mutation segregated perfectly with 
GH- and GH/PRL-producing adenomas. AIP mutation screening was also 
performed for 45 acromegaly patients belonging to a population based cohort 
from Northern Finland (Kauppinen-Makelin et al. 2005), and six c.40C>T and one 
c.469-1G>A mutations were detected (Vierimaa et al. 2006). Thus, AIP mutations 
accounted for 16% (7 out of 45) of all acromegaly patients, and 40% of those 
diagnosed under the age of 35 years (6/15). AIP as a novel pituitary adenoma 
predisposing gene was further confirmed with the detection of a nonsense 
mutation c.910C>T (p.Arg304X) in two Italian acromegalic siblings (Vierimaa et 
al. 2006). 
 
Loss of the wild-type allele was seen in all studied GH-, PRL, and GH/PRL-
producing tumors from AIP mutation carriers (Vierimaa et  al. 2006). Authors 
concluded that the mutations predispose to at least these tumor types, that the 
gene is likely a tumor suppressor, and that the penetrance of PAP appears to be 
low. The tumor suppressor role of AIP was further confirmed with functional 
studies (Heliovaara et  al. 2009; Leontiou et  al. 2008). In general, a typical PAP 
patient (i.e. AIP mutation carrier) is diagnosed at a young age and the family 
history of pituitary adenomas might not be convincing (Vierimaa et al. 2006).   
 
AIP gene, also known as XAP2 or ARA9, locates at 11q13 and the six exons code 
for a 330 aa long protein (Ensembl 54). An FKBP-homology domain is located in 
the amino-terminus of AIP and three tetratricopeptide repeats (TPR), which 
mediate protein-protein interactions, in the carboxy-terminal region. AIP is 
known to form a complex with aryl hydrocarbon receptor (AHR), with two 90 
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kDa heat-shock proteins (HSP90), and with p23 (Carver and Bradfield 1997; Chen 
and Perdew 1994; Kazlauskas et  al. 1999). Interactions have been shown at least 
with PDE4A5, PDE2A, PPAR- , BIRC5, THR 1, TOMM20, EBNA3, and RET 
(Bolger et al. 2003; de Oliveira et al. 2007; Froidevaux et al. 2006; Kang and Altieri 
2006; Kashuba et al. 2000; Sumanasekera et al. 2003; Vargiolu et al. 2009; Yano et al. 
2003). Many of these proteins can be linked to pituitary tumorigenesis such as 
AHR that is involved in xenobiotic-induced metabolism and in the absence of 
xenobiotics in e.g. cell proliferation, cell adhesion, and migration (Barouki et  al. 
2007). Interestingly, a recent study showed significantly reduced 
immunoreactivity for AHR translocator (ARNT) and somewhat increased 
localization of AHR in the nucleus in the AIP mutation-positive adenomas 
compared to the mutation-negative ones (Heliovaara et  al. 2009). This indicated 
that these molecules are potentially involved in tumorigenesis of AIP mutation-
positive pituitary tumors. 
 
Many interaction partners of AIP are known but the mechanism between how the 
loss of AIP tumor suppressor gene leads to the pituitary tumorigenesis remains to 
be elucidated. Hopefully the ongoing functional studies, both in vitro and in vivo, 
will clarify this issue.  
2.4.2.4. Isolated Familial Somatotropinomas (IFS) 
 
IFS (Table 3) is defined as follows: at least two individuals of acromegaly or 
gigantism in a familial setting in the absence of MEN1 and CNC (Gadelha et al. 
1999). These patients are often diagnosed with macroadenomas at a young age 
(Soares and Frohman 2004). Efforts to identify the predisposing locus have shown 
loss of heterozygocity (LOH) in chromosome 11q13 but MEN1, locating in this 
area, was not mutated (Gadelha et al. 1999; Tanaka et  al. 1998; Teh et  al. 1998; 
Yamada et  al. 1997). At the same locus Vierimaa et al. (2006) reported truncating 
mutations in AIP in three families with at least two cases of pituitary adenomas. 
Two of these families harbored only GH-producing adenomas e.i. IFS. Later on, 
the following mutation screening studies have identified additional IFS cases 
with AIP mutations (e.g. Daly et  al. 2007b; Iwata et  al. 2007; Leontiou et  al. 2008; 
Toledo et al. 2007). 
2.4.2.5. Familial Isolated Pituitary Adenomas (FIPA) 
 
Compared to IFS, FIPA is a wider clinical entity with familial cases of pituitary 
adenomas not restricted only to GH-producing adenomas (Table 3). These 
families can be divided into subcategories according to tumor phenotype 
between the family members. Homogeneous are those families where only one 
tumor type exists and heterogeneous those with varying tumor types (Daly et al. 
2006a). All subtypes of pituitary adenomas have been identified in heterogeneous 
kindreds but often at least one GH-producing or PRL-producing adenoma is 
present (Beckers and Daly 2007). The majority of the pituitary adenomas 
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(approximately 75%) in the FIPA cohort are PRL-producing, GH-producing, or 
GH/PRL-producing adenomas (Beckers and Daly 2007). Moreover, FIPA patients 
are often diagnosed at a younger age and with larger pituitary adenomas 
compared to corresponding sporadic pituitary counterparts (Beckers and Daly 
2007).  
 
Pituitary adenomas in the FIPA families were reported to be significantly larger 
in the AIP mutation-positive cases when compared to the AIP mutation-negative 
ones (Daly et  al. 2007b). Authors concluded that the pituitary adenomas in the 
AIP mutation-positive patients were of an aggressive type. Indeed, preliminary 
results have indicated a poor response to therapy in the AIP mutation-positive 
patients (Daly et al. 2008; Leontiou et al. 2008). However, the majority of the FIPA 
patients do not harbor AIP mutations and therefore the underlying genetic 
component(s) of FIPA remains to be elucidated. 
2.4.2.6. Multiple Endocrine Neoplasia type 4 (MEN4) 
 
MEN4 (MIM610755; Table 3) is an autosomal recessive condition with MEN1-
related tumors. Identification of this novel syndrome was based on a naturally 
occurring rat strain with features overlapping with both human MEN type 1 and 
type 2 (Fritz et  al. 2002). These included bilateral pheochromocytomas, 
parathyroid adenomas, medullary thyroid cell neoplasia, parathyroid 
hyperplasia, pituitary adenomas, and endocrine pancreas hyperplasia (Fritz et al. 
2002; Pellegata et  al. 2006). A recent study identified a homozygous germ-line 
mutation in Cdkn1b/p27Kip1 gene in these rats (Pellegata et  al. 2006). In the same 
study, a germ-line mutation in humans was reported in a family with two 
individuals diagnosed with MEN1-related tumors: the proband was diagnosed 
with primary hyperparathyroidism and pituitary adenoma and her sister with 
renal angiomyolipoma. Although the wild-type allele was retained in the tumor 
tissue, immunohistochemical staining of the CDKN1B/p27Kip1 gene protein 
product, called p27, showed no protein in the tumor tissue (Pellegata et al. 2006). 
 
The CDKN1B/p27Kip1 gene at 12q13, has three protein coding transcripts 
containing two (205 aa) or three (104 aa and 198 aa) exons (Ensembl 54). Nuclear 
p27 negatively regulate the cell cycle by inhibiting cyclin and cyclin-dependent 
kinase complexes. Previous knockout mouse models had already indicated that 
this gene is involved in multiple endocrine neoplasia (Fero et al. 1996; Kiyokawa 
et al. 1996; Nakayama et al. 1996). Despite the efforts to screen human pituitary 
adenomas, neither pathogenic mutations nor loss of heterozygocity was found 
(e.g. Ikeda et  al. 1997; Tanaka et  al. 1997). However, lowered or even absent 
expression of p27 has been reported in most human pituitary adenomas 
(Bamberger et al. 1999; Komatsubara et al. 2001; Lidhar et al. 1999). Interestingly, 
the regulation of the expression of p27 includes both menin (Karnik et al. 2005; 





Additional CDKN1B/p27Kip1 mutations in humans would strengthen the role of 





3. AIMS OF THE STUDY 
 
I       Clarify the clinical and molecular identification of PAP patients 
 
II     Analyze somatic AIP mutations in sporadic endocrine neoplasia  
 
III    Analyze germ-line AIP mutations in familial non-medullary thyroid cancer 
 
IV    Study the role of CDKN1B/p27Kip1 in MEN-like phenotype 
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4. MATERIALS AND METHODS 
4.1. Subjects 
 
This study was approved by the Ministry of Social Affairs and Health, the Ethics 
Review Committees of the Hospital District of Helsinki and Uusimaa, and the 
Department of Medical Genetics of the University of Helsinki. The permission to 
use patient samples was obtained either with appropriate informed consent or 
with the permission of the National Authority for Medicolegal Affairs. Detailed 
information of samples can be found from the corresponding publications or 
from their supplementary material.  
4.1.1. Pituitary adenoma patient samples (I, II, IV) 
 
Altogether 460 samples were analyzed in study I. This cohort consisted of 
heterogeneous pituitary adenoma patients originating from several populations 
from Europe and the United States. The samples can be divided into the 
following subcategories: a) young acromegaly patients consisting of 27 samples 
from German patients (<40 years at the time of surgery) and 36 from Finnish 
patients (<45 years at the time of diagnosis), b) unselected acromegaly patients 
including 71 samples from Italian patients, c) unselected pituitary adenoma patients 
consisting of 113 samples from American patients and 122 from Polish patients, 
and d) MEN1 suspected patients without MEN1-gene mutations including 55 
samples from Spanish patients and 36 from Dutch patients. 
 
Fifty pituitary adenoma samples were available to study AIP protein expression 
(study I). Two patients with PRL-producing and seven with GH-producing 
adenomas had c.40C>T mutation. Three GH-producing adenomas were from 
patients with c.280-1G>C, c.824_825insA, or c.469-1G>A mutation. AIP mutation-
negative tumors accounted for 32 GH-producing and five PRL-producing 
adenomas, and one GH- and PRL-negative adenoma.  
 
In study II, thirty-two sporadic Finnish pituitary adenoma samples were 
analyzed: nine were PRL-producing and 23 GH-producing adenomas. Twenty-
one of the GH-producing adenomas originated from the population-based cohort 
of 54 acromegaly patients diagnosed in five Finnish university hospitals during 
1980-1999 (Kauppinen-Makelin et  al. 2005; Vierimaa et al. 2006). As previously 
reported, 20 samples from this cohort of 54 patients are AIP mutation-negative 
(Vierimaa et al. 2006).  
 
Thirty-five out of 36 suspected MEN1 patients (also in study I) without MEN1- or 
AIP-mutation from Netherlands and one additional suspected MEN1 patient 
from Germany were included in study IV. Furthermore, sequence analysis 
consisted of 34 out of 36 young Finnish acromegaly patients (also in study I), 16 
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AIP-mutation negative sporadic pituitary adenoma patients (Oulu University 
hospital, also in study I), and 19 familial acromegaly/pituitary adenoma patients 
originating from various nationalities. All of the samples were AIP-mutation 
negative. 
4.1.2. Sporadic endocrine tumors (II) 
 
The tumors analyzed from tissues of the endocrine system other than the 
pituitary gland, included 61 Finnish and 18 Danish samples. The samples were 
from the thyroid gland (26 tumors), the adrenal gland (19 tumors), lung, cecum, 
appendix and small intestine (16 neuroendocrine tumors), and the parathyroid 
gland (8 tumors). Four paragangliomas, four pancreatic endocrine tumors, and 
two mixed endocrine-exocrine tumors were also included in study II. 
4.1.3. Familial thyroid cancer patient cohort (III) 
 
Up to 7% of all thyroid tumors belong to the clinical entity of familial non-
medullary thyroid cancer (NMTC). Eighty percent of a familial NMTC cohort, 
including 261 families, did not connect to previously identified predisposing 
locus 2q21 and 19p13.2 (Canzian et al. 1998; McKay et al. 2001; McKay et al. 2004). 
AIP was sequenced in 93 index cases of these non-linked families. Eighty-five 
patients were diagnosed with papillary thyroid cancer (PTC), one with PTC and 
Hashimoto thyroiditis, one with PTC and hypothyroidism, and one with PTC 
and colloidal adenoma. Two patients had micropapillary thyroid cancer, two had 
multinodular goiter, and one had thyroid adenoma.  
4.1.4. Healthy control samples (I, II, III, IV) 
 
Control DNA samples were received from 749 unrelated, anonymous, healthy 
individuals. These samples consisted of 288 Caucasians from UK (Human 
Random Control DNA panel, Porton Doen, Salisbury, Wiltshire, UK), 110 
Caucasians from the Centre d’Étude du Polymorphisme Humain (Fondation Jean 
Dausset-CEPH, Paris, France), 209 Finnish Red Cross blood donors, 90 Germans 
(Leipzig University, Germany), and 52 Italians (Treviso General Hospital, Italy). 
The analyzed control samples in each study are described in corresponding 
publications. 
4.2. Analysis methods 
4.2.1. Direct sequencing (I, II, III, IV) 
 
Genomic DNA was extracted from blood or paraffin-embedded tissue according 
to standard protocols (Kannio et al. 1996; Lahiri and Nurnberger 1991; Shibata et 
al. 1988). Primer pairs used for sequencing the coding region of AIP and the 
flanking intronic areas have been previously described (Vierimaa et al. 2006). 
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CDKN1B/p27Kip1 primer pairs were designed by using Primer3 
(http://frodo.wi.mit.edu/primer3), and are presented in the supplementary 
material of the original publication (study IV). In both genes, tumor-derived 
DNA was amplified in shorter fragments compared to normal DNA.  
 
PCR products were analyzed by electrophoresis using 2% agarose gel and the 
specifically amplified products were purified using ExoSAP-IT purification kit 
(USB Corporation). Purified PCR-fragments were sequenced using the Big Dye 
3.1 Termination chemistry on an ABI3730 DNA sequencer (Applied Biosystems).  
 
LOH analysis was performed on the tumor-derived DNA. From the sequence 
chromatograms the peak heights/areas between the wild-type and the mutant 
allele were compared. LOH was detected when the wild-type allele was either 
completely or nearly completely disappeared, when compared to the mutant 
allele. 
4.2.2. Immunohistochemistry (IHC) (I, III, IV) 
 
Immunoreactions against AIP (1:4000, AIP SP5213P; Acris Antibodies) and p27 
(1:500, p27Kip1, clone 57; BD Biosciences) were done according to standard IHC 
procedures. The AIP IHC is introduced shortly. Five-micrometer-thick sections 
were cut from the paraffin blocks and pre-warmed from 30 minutes up to one 
hour at 55°C. After deparaffinization and rehydration in graded alcohol series, 
antigen retrieval was carried through with either 0.01 M citrate (pH 6.0) buffer in 
a microwave oven at 800 W for 2 min and at 300 W for 10 min or in 0.01 M Tris-
EDTA (pH 6.0) buffer in a microwave oven at 800 W for 2 min and at 300 W for 
15 min. The slides were allowed to cool for 20 min and rinsed with PBS. 
Thereafter, primary antibody was incubated for 30 min at room temperature, 
followed by rinsing in PBS, after which the bound antibodies were detected using 
diaminobenzidine (DAKO, Copenhagen, Denmark) with hematoxylin counter 
stain. The slides were dehydrated in graded alcohol series, embedded in xylene, 
and covered. 
4.2.3. In silico analysis (I, III, IV) 
 
Computational programs were used to predict whether the detected intronic, 
silent, or missense changes affect splicing. The used in silico splice site prediction 
programs were Berkeley Drosophila Genome Project, ESEfinder 2.0, Splice Scan, 
Alternative Splice Site Predictor, and NetGene2 (Brunak et al. 1991; Cartegni et al. 
2003; Hebsgaard et al. 1996; Reese et al. 1997; Smith et al. 2006; Tchourbanov and 




5.1. Molecular analysis of PAP (I) 
 
The identification of AIP as a predisposing gene was originally described in a 
homogeneous population (Vierimaa et al. 2006). To clarify the clinical features of 
this condition in a more heterogeneous pituitary adenoma setting, AIP was 
sequenced in 460 pituitary adenoma patients from the European and North 
American populations. Potentially pathogenic mutations were observed at low 
frequencies (Table 4). AIP mutations were the most common in young 
acromegaly patients from Germany (2/27 or 7.4%) and Finland (2/36 or 5.5%). 
Mutations were less common in unselected pituitary adenoma patients from 
North America (2/113 or 1.8%) and Poland (1/122 or 0.8%). Also, AIP mutations 
were identified in suspected MEN1 patients without MEN1 mutations from Spain 
(1/55 or 1.8%) and the Netherlands (1/36 or 2.8%). None of the studied Italian 
unselected acromegaly patients harbored AIP mutations.  
 
Table 4. Detected AIP mutations from pituitary adenoma patients from European 
and North American populations. Only the potentially pathogenic mutations are 
presented. None of these variations were present in the control samples. 
 











     
German c.66_71del Yes GH 20 yr Yes (acromegaly) 
German c.[878_879delinsGT; 
c.880_891del] 













Finnish c.40C>T NA GH 41 yr No 
 












































LOH, loss of heterozygocity e.g. loss of wild-type allele; NA, not available 
a Age at the time of operation, the age at the time of diagnosis is unknown. 
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Other detected AIP variations were c.100-18C>T in one German sample, c.47G>A 
(p.Arg16His) in one Italian, in one American with Polish roots, and in three 
Polish samples, c.906G>A (p.=) in three American samples, and c.696G>C (p.=) in 
one Polish sample. These variations were considered as a rare polymorphism 
according to in silico prediction (c.100-18C>T, c.906G>A, c.696G>C), negative LOH 
analyze (c.47G>A) and/or detection of variations also in the healthy controls 
(c.100-18C>T, c.47G>A, c.906G>A). 
 
To help in identifying the AIP mutation-positive patients, the possibility to use 
immunohistochemistry as a pre-screening tool was studied. AIP mutation-
positive tumors were from patients with c.40C>T, c.280-1G>C, c.824_825insA, or 
c.469-1G>A mutation.  Most of AIP mutation-positive tumors (9/12 or 75%) 
showed complete loss of AIP in the cytoplasm and nucleus (Fisher’s Exact test, 
p=0.000004; Fig. 4). Positive AIP immunoreactions in these tumors may be due to 
e.g. unspecific staining or presence of nonfunctional yet immunoreactive AIP 
protein. Positive immunoreactions of AIP were detected in most of the AIP 
mutation-negative tumors (36/38 or 95%).  Therefore, AIP IHC showed 75% 
sensitivity and 95% specificity for truncating AIP germ-line mutations. This 




Figure 4. AIP IHC stainings with 40x magnification. (A) AIP mutation-negative 
adenoma shows positive immunoreaction against AIP. (B) Pituitary adenoma 
from a patient with c.40C>T mutation shows the lack of AIP protein whereas 
peripheral blood leukocytes, indicated by black arrows, display positive 
immunoreaction.   
5.2. Somatic AIP mutation screening in sporadic endocrine neoplasia (II) 
 
To study the possible somatic mutations of AIP in sporadic endocrine tumors, 
thirty-two pituitary adenomas and 79 other tumors of the endocrine system were 
analyzed. No somatic mutations were identified in the studied tumors. However, 
two PRL-producing adenoma patients harbored the Finnish founder mutation 
c.40C>T (p.Gln14X) and one thyroid adenoma patient a potential polymorphism 




c.40C>T was detected in two patients with the PRL-producing pituitary adenoma. 
These patients were diagnosed at the age of 35 years and both of the tumor 
tissues showed the complete loss of the wild-type allele. One mutation-positive 
patient was a male with no family history of the endocrine tumors. The mutation 
was also present in his germ-line. The other mutation carrier was a female whose 
normal tissue and family history information were not available.  
 
The other detected germ-line variation was c.69A>G in a female patient with 
thyroid adenoma diagnosed at the age of 60 years. This variation was present in 
the corresponding normal tissue and wild-type allele was retained in the tumor 
tissue. Because of this and previous observations of c.69A>G in the healthy 
controls (five out of 532) and in Finnish colorectal cancer samples (6/373), this 
variation was considered as a germ-line polymorphism (study I; Georgitsi et  al. 
2007; Vierimaa et al. 2006). 
5.3. Screening of AIP in familial non-medullary thyroid cancer (NMTC) cases 
(III) 
 
The possible germ-line mutations of AIP were studied in index patients from 93 
NMTC families. Two previously reported AIP variations were detected. One 
patient, with PTC and colloidal adenoma diagnosed at the age of 44 years, 
harbored c.47G>A (p.Arg16His). The other patient, with unilateral PTC 
diagnosed at the age of 36 years, harbored c.36G>A (p.=). These variations did not 
segregate in the corresponding families. According to in silico analysis, neither of 
the variants had predicted effects on splicing. Tumor tissues were not available 
for LOH analysis. 
 
In the previous studies, c.47G>A has been identified in fourteen pituitary 
adenoma patients, two Finnish colorectal cancer patients, and three healthy 
controls (study I; Buchbinder et  al. 2008; Cazabat et  al. 2007; Daly et  al. 2007b; 
Georgitsi et  al. 2007; Yaneva et  al. 2008). Whereas c.36G>A has been detected in 
one Finnish prostate cancer patient and one sporadic acromegaly patient, but all 
of the studied 802 healthy controls have been negative for this change (Cazabat et 
al. 2007; Georgitsi et  al. 2007). Both variants were considered as rare 
polymorphisms, although the pathogenic potential of c.36G>A cannot be totally 
excluded. 
 
In addition, one follicular thyroid adenoma from an AIP mutation-positive (c.469-
1G>A) patient from an additional cohort was available to the study. No LOH was 
seen in the tumor tissue and the AIP IHC was positive in the adenoma and the 





5.4. The analysis of CDKN1B/p27Kip1 mutations in endocrine neoplasia (IV) 
 
The germ-line mutation of CDKN1B/p27Kip1 was reported in one patient with 
multiple endocrine neoplasia (Pellegata et  al. 2006). To further study the role of 
CDKN1B/p27Kip1 in multiple endocrine neoplasia, mutation screening was 
performed in 36 clinically suspected MEN1 patients without MEN1 gene 
mutation. Furthermore, nineteen familial acromegaly or familial pituitary 
adenoma patients, and 50 sporadic acromegaly patients were included in the 
study. One suspected MEN1 patient carried 19-bp duplication (c.59_77dup) in the 
coding region of CDKN1B/p27Kip1 gene. This mutation causes frame shifting 
change at Serine-27. It creates a new reading frame ending in a stop codon at 69 
residues earlier than the wild-type allele. The sequencing of DNA extracted from 
the neuroendocrine cervical carcinoma revealed the loss of the wild-type allele, 
and the IHC staining confirmed the absence of p27 in this tumor. This 
CDKN1B/p27Kip1 mutation was the second reported mutation in humans. 
 
The other detected CDKN1B/p27Kip1 gene variation was a silent change c.426G>A 
(p.=) in one young sporadic acromegaly patient. According to in silico analysis, 





6.1. The PAP phenotype 
 
The Finnish population is overall genetically homogeneous due to the relatively 
small founder populations, the small genetic drift, and the isolated location 
resulting from geographical, linguistic, and religious reasons (Peltonen 1997).  
Thus, rare conditions with low-penetrance can be found as clusters. This 
facilitates the identification of the predisposing gene(s) as was the case in the 
identification of the AIP mutations in PAP (Vierimaa et  al. 2006). In the initial 
study, AIP mutations were relatively frequent in a population-based cohort from 
Northern Finland: 16% in GH-producing pituitary adenomas, and 40% in a 
subset of patients diagnosed under the age of 35 years (Vierimaa et al. 2006). To 
gain insight into the PAP phenotype and the mutation frequencies it was relevant 
to study more heterogeneous sample materials as well. 
6.1.1. AIP mutation frequencies in diverse clinical settings (I) 
 
In study I, the contribution of AIP mutations was studied in pituitary adenoma 
patients from genetically heterogeneous populations from Europe and North 
America. If taking into account the previously reported two patients belonging to 
the same Italian cohort of which 71 were analyzed in study I (Vierimaa et  al. 
2006), AIP mutations were found from all of the studied clinical subcategories 
(0.8-7.4%). The highest mutation frequencies were detected in young 
acromegaly/gigantism patients from Germany (2/27 or 7.4%) and Finland (2/36 or 
5.5%).  Among all studied AIP mutation-positive patients the average age at 
diagnosis was 23.8 years. Additional studies have detected similar ages in the 
AIP mutation-positive patients (average ~25 years) which are lower than in the 
mutation-negative ones (average ~38 years) (Daly et  al. 2007b; Leontiou et  al. 
2008). Besides the young age of the AIP mutation-positive patients, the majority 
of these patients did not have family history of pituitary adenomas. These 
observations are in concordance with the original study by Vierimaa et al. (2006) 
where the young age of onset and the low penetrance of this condition were 
reported. In the following studies, even up to 66% penetrance has been suggested 
(Daly et al. 2007b; Iwata et al. 2007; Khoo et al. 2009; Leontiou et al. 2008; Naves et 
al. 2007; Toledo et  al. 2007). However, this high frequency may reflect a bias 
caused by the incomplete data from some of the families. More accurate and age-
related penetrance estimation requires additional AIP mutation-positive families 
to be studied and extended time period of surveillance. 
 
After the initial study of Vierimaa et al. (2006) and followed by study I, AIP 
mutation status has been studied in familial and sporadic pituitary adenoma 
patients. Daly et al. (2007b) performed AIP mutation screening in 73 FIPA 
families. Mutations accounted for 15% of these families and for 50% of those 
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families with only GH-producing adenomas e.i. IFS (Daly et al. 2007b). A similar 
trend was seen in 26 FIPA families where 35% of the families were AIP mutation-
positive (Leontiou et al. 2008). Additional familial cases with AIP mutations have 
also been reported (Georgitsi et  al. 2008b; Iwata et  al. 2007; Jennings et  al. 2009; 
Khoo et al. 2009; Toledo et al. 2007). AIP mutations seem to account for less than 
2% of the sporadic pituitary adenomas (study II; Barlier et al. 2007; Buchbinder et 
al. 2008; Cazabat et al. 2007; Digiovanni et al. 2007; Georgitsi et al. 2008a; Igreja et 
al. 2009; Iwata et  al. 2007; Leontiou et  al. 2008; Vierimaa et  al. 2006; Yaneva et al. 
2008; Yu et al. 2006). The majority of the AIP mutation-positive patients have been 
diagnosed with GH-producing adenomas, but cases with PRL-, ACTH-producing 
adenomas or NFPAs have also been reported (study I; study II; Daly et al. 2007b; 
Georgitsi et al. 2008b; Leontiou et al. 2008). Recently, male predominance in PAP 
was suggested: 70% of the reported AIP mutation-positive patients were males (p 
< 0.001) (Cazabat et  al. 2009). This association remains statistically significant in 
an update of the AIP mutation-positive patients (62%, 71 M/44 F, p  0.014, Chi-
square test). Additional AIP mutation-positive patients and careful clinical 
examinations will show if males are truly at a higher risk of developing pituitary 
adenomas in PAP. 
 
Approximately 40 different AIP mutations, scattered throughout the coding 
region, have so far been identified (Fig. 5).  Interestingly, most of the pathogenic 
missense mutations occur in a region between codons 241-304 in the two last 
exons of AIP. Two of the TPR motifs, which are critical for protein-protein 
interactions, are located in this area. In addition, the five last amino acids (codons 
325-330) of the protein are required for binding to AHR (Bell and Poland 2000). 
 
 
Figure 5. A schematic figure of AIP with all pathogenic germ-line mutations 
reported in the literature by November 2009. The exon boundaries of the AIP 
gene are indicated by dashed lines. The pink box shows the location of FKBP 




A large portion of the familial and sporadic pituitary adenoma cases are not 
explained by the known genes predisposing to pituitary adenomas. LOH of 
11q13 is observed in the pituitary adenomas without detectable MEN1 or AIP 
mutation (e.g. Gadelha et al. 1999; Tanaka et al. 1998; Teh et al. 1998; Yamada et al. 
1997). One explanation might be the limitations of the current sequencing 
methods, as seen in a recent study where large genomic deletions in the AIP area 
were detected in patient samples previously sequenced to be AIP mutation-
negative (Georgitsi et  al. 2008b). However, it is possible that unidentified 
predisposing gene(s) still lays in the 11q13.  
6.1.2. The IHC in identification of PAP (I) 
 
The lack of family history and the low frequency of AIP mutations in randomly 
selected pituitary adenoma patients create a challenge for the identification of the 
PAP patients. Routine screening of AIP in all pituitary adenoma patients seems 
unreasonable. Since the pituitary adenomas are stained against hormones for 
diagnostic purpose in many laboratories, we wanted to test the specificity and 
sensitivity of the AIP IHC.  
 
In study I, the AIP IHC using a polyclonal antibody against mouse recombinant 
AIP showed high specificity (95%), but weaker sensitivity (75%). The AIP IHC 
has also been tested in later studies. A monoclonal antibody against the human 
AIP with amino-terminal epitope (FKBP region) showed decreased 
immunostaining in a pituitary adenoma sample with early truncating AIP 
mutation (p.Glu174fs) (Naves et al. 2007). In another study, the AIP IHC with the 
same antibody showed weak immunoreactivity in the pituitary adenomas with 
AIP mutation  (e.g. p.Gln82fs, p.Arg304X, and p.Gln285fs), albeit 
immunoreactivity was also diminished in the adenomas with probably non-
pathogenic variations (e.g. c.279+23C>T and c.468+16G>T) (Jaffrain-Rea et  al. 
2009). Moreover, immunostaining with the same AIP antibody in the pituitary 
adenoma samples with p.Arg304X or p.His274fs mutation showed positive 
staining of the protein (Leontiou et  al. 2008). In some of these AIP mutation-
positive adenomas, the positive immunoreaction may be due to carboxyl-
terminal location of the mutation and amino-terminal location of the antibody 
epitope.  
 
Discrepancies in the sensitivities between the AIP IHC studies may arise from 
different reasons. For example, the IHC assays may differ between the 
laboratories. It is also possible that carboxyl-terminal or missense mutation leads 
to a stable and immunoreactive, yet possibly dysfunctional, protein. Thus, the 
nature and position of the mutation and the selection of antibody are critical. 
Improving the AIP IHC requires further optimization with new carboxyl-
terminal AIP antibodies. Functional AIP IHC could be useful at least as a pre-
screening tool to identify the potential PAP patients. For instance, IHC screening 
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of tumors in HNPCC, also known as Lynch syndrome, has been successfully 
used even as a diagnostic tool (Hampel et al. 2005). 
6.2. Somatic AIP mutations are rare or non-existent in sporadic endocrine 
neoplasia (II) 
 
As already mentioned, germ-line AIP mutations predispose mainly to GH-
producing adenomas and less frequently to PRL-, ACTH-producing adenomas, 
and NFPAs. Pituitary adenomas also occur in MEN1 and CNC syndromes. 
Somatic mutations in MEN1 and PRKAR1A are rare in sporadic pituitary 
adenomas (e.g. Wenbin et al. 1999; Yamasaki et al. 2003). Such mutations are seen 
in some other tumors related to these syndromes (e.g. Farnebo et  al. 1998; 
Sandrini et al. 2002b). Thus, we studied the occurrence of somatic AIP mutations 
in the pituitary adenomas and also, for the first time, in non-pituitary endocrine 
tumors.  
 
None of the studied sporadic pituitary adenomas harbored purely somatic 
mutations. However, the Finnish founder mutation was detected in two PRL-
producing adenomas from individuals diagnosed at a young age (two out of 
nine, 22%). For one of the patients the mutation was confirmed to be in the germ-
line. This patient, from whom information was available, had no family history of 
endocrine tumors. These results supported the previous observations that AIP 
mutations also predispose to PRL-producing adenomas (Daly et  al. 2007b; 
Vierimaa et al. 2006).  
 
Thus far the number of PRL-producing adenomas, in which somatic AIP 
mutations has been studied, is limited. This may be because of the infrequent 
surgery of the PRL-producing adenomas; tumors have a slow growth rate and 
good response to the therapy (Spada et  al. 2005). Therefore, further studies are 
required to clarify the possible contribution of somatic AIP mutations in the PRL-
producing adenomas.  
 
In study II, somatic AIP mutations were also examined in the sporadic GH-
producing adenomas, but all samples were mutation-negative. This is in 
concordance with the previous studies which have not identified somatic 
mutations in that particular tumor type (Barlier et  al. 2007; Iwata et al. 2007). 
These results indicate that somatic AIP mutations  do  not  have  a  major  
contribution to the formation of the sporadic GH-producing adenomas. Actually, 
many tumor susceptibility genes are only rarely somatically mutated in the 
respective sporadic tumors such as BRCA1/2 in the sporadic breast tumors (Khoo 
et al. 1999; Yang et al. 2002). 
 
In this study, the occurrence of somatic AIP mutations were analyzed for the first 
time in non-pituitary endocrine tumors. No somatic AIP mutations were 
detected. Results suggest that AIP mutations do not seem to be strongly involved 
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in the development of these tumors. In previous studies, LOH of 11q13 has been 
reported in adrenal carcinomas from two AIP mutation-positive patients 
(Leontiou et  al. 2008; Toledo et  al. 2008). However, a larger number of PAP 
families and additional evidence is needed to clarify whether AIP mutations are 
predisposing to adrenal tumors since LOH of 11q13 is a frequent event in this 
tumor type (Luccio-Camelo et al. 2004).  
6.3. AIP mutations seem not to be involved in familial non-medullary thyroid 
cancer (III) 
 
NMTC occurs with a greater frequency than expected in familial syndromes such 
as CNC (Malchoff and Malchoff 2006). Familial NMTC is a distinct clinical 
condition characterized by a higher degree of tumor aggressiveness and an 
increased mortality (Grossman et  al. 1995). Several susceptibility loci for familial 
NMTC have been suggested (e.g. Cavaco et  al. 2008; McKay et  al. 2001), but the 
main genetic components are still unknown. Thyroid disorders have also been 
identified in FIPA, and PAP families (O Vierimaa and PI Salmela, unpublished 
observations; Beckers and Daly 2007). Thus, the possible role of AIP in familial 
NMTC was examined in study III. Sequencing of AIP did not reveal potentially 
pathogenic AIP mutations indicating that germ-line AIP mutations have little or 
no role in the genesis of familial NMTC.  
 
The possible loss of AIP in thyroid tumors was studied in one tumor sample from 
a Finnish AIP mutation-positive patient. LOH and immunohistochemical 
analyses suggested that the immunoreactive protein seems to be present in this 
particular tumor tissue. Interestingly, patients with GH-producing adenomas are 
at a higher risk of developing non-toxic nodular goiters. Also, these patients have 
a somewhat elevated risk of thyroid cancer compared to the general population 
(e.g. Herrmann et  al. 2004; Kurimoto et  al. 2008). This seems to be linked to the 
increased plasma levels of IGF-I in patients with GH-producing adenomas (Siegel 
and Tomer 2005). Thus, at least some of the thyroid disorders seen in the AIP 
mutation-positive patients may be due to the elevated IGF-I levels. On the other 
hand, thyroid disorders are quite common in the general population (up to 7%) 
(Roman 2003) and those tumors may occur just by chance in the AIP mutation-
positive patients.  
6.4. AIP in tumorigenesis 
 
So far the number of endocrine tumors screened for AIP mutations, other than 
pituitary adenomas, is limited. Thus, AIP mutations may be identified by 
screening additional non-pituitary endocrine tumors. Besides endocrine tumors, 
AIP mutations have been studied in common cancer types, including colorectal 
cancer, breast cancer, and prostate tumors, with the negative results (Georgitsi et 
al. 2007). Even though AIP is ubiquitously expressed in all human tissues, with 
current knowledge AIP mutations seem to predispose only to pituitary 
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adenomas. Thus, AIP could be associated to tissue selective tumorigenesis. This 
was supported in a recent study where the silencing of Aip resulted in increased 
cell proliferation in a rat pituitary cell line (GH3), but not in two other studied 
cell lines (HEK293 and HeLa) (Heliovaara et  al. 2009). In the same study, IHC 
analysis showed that ARNT was less frequently expressed in the AIP mutation-
positive tumors compared to the mutation-negative ones. Again the tissue-
selectivity was indicated since the reduction of Arnt was only seen in the GH3 
cell line after Aip-silencing (Heliovaara et  al. 2009). Heliovaara et al. (2009) also 
noticed that the expression of the nuclear AHR was somewhat increased in the 
AIP mutation-positive adenomas compared to the mutation-negative ones. Thus, 
ARNT and AHR were suggested to be involved in the pituitary tumorigenesis in 
the AIP mutation-positive tumors.  
 
Aberrant cAMP signaling is often detected in pituitary tumorigenesis (Boikos and 
Stratakis 2007b). This signaling is also possibly involved in the pituitary 
tumorigenesis of the AIP mutation-positive tumors. AIP targets PDE2A to the 
AHR complex (de Oliveira et al. 2007). This binding ensures AHR retention in the 
cytoplasm by lowering the local cAMP concentrations (de Oliveira et al. 2007). 
Thus, the lack of functional AIP may lead to elevated local cAMP levels and 
cause the translocation of AHR to the nucleus (Heliovaara et al. 2009). 
Furthermore, the cAMP-mediated translocation of AHR prevents the formation 
of the AHR/ARNT complex (Oesch-Bartlomowicz et  al. 2005). Heliovaara et al. 
(2009) suggested that the disturbances in the formation of AHR/ARNT, possibly 
also HIF1- /ARNT, complex may unbalance the transcription of target genes of 
this complex leading to pituitary tumorigenesis. 
 
Aip knock-out  mice  (Aip-/-) were reported to show embryonic lethality 
accompanied by cardiac malformations (Lin et al. 2007). The phenotype of these 
Aip-/- mice was different from those of Ahr-/- and Ppar -/- mice. Thus, Lin et al. 
(2007) suggested that Aip seems to have a role in another pathway distinct from 
xenobiotic-induced metabolism. In the same study, heterozygous Aip+/- mice 
appeared phenotypically normal and fertile, but the possibility of endocrine 
tumor formation was not studied. 
In a recent study, a tendency towards a higher risk of pituitary adenomas was 
seen after massive exposure to dioxin after the Seveso accident, Italy, in 1976 
(Pesatori et  al. 2008). The tumors that occurred did not include GH-producing 
adenomas, which is the main tumor type in PAP. Moreover, it should be noted 
that the prevalence of pituitary tumors was not statistically significant (Pesatori et 
al. 2008). Thus, the direct activation of AHR, leading to xenobiotic-induced 
metabolism, did not cause increased risk of pituitary adenoma development.  
 
Certainly the mechanism how the loss of functional AIP leads to tumor formation 
requires further studies. Functional studies and work with animal models should 
help to resolve this issue in the future. 
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6.5. The role of CDKN1B/p27Kip1 in multiple endocrine neoplasia (IV) 
 
Recently, a germ-line CDKN1B/p27Kip1 mutation was reported in one family with 
multiple endocrine neoplasia (Pellegata et  al. 2006). In this family, the MEN1-
related tumors included GH-producing pituitary adenoma, primary 
hyperparathyroidism, and angiomyolipoma. To further study the role of 
CDKN1B/p27Kip1 gene in endocrine neoplasia, we performed a mutation screening 
of CDKN1B/p27Kip1 in suspected MEN1 patients without MEN1 gene mutation. 
Also the contribution of CDKN1B/p27Kip1 mutations in the familial and sporadic 
pituitary adenomas was studied. 
 
In this study, we were able to confirm the finding of Pellegata et al. (2006) by 
publishing the second germ-line CDKN1B/p27Kip1 mutation in a clinically 
suspected MEN1 patient. This patient had three MEN1-related tumors: small-cell 
neuroendocrine cervical carcinoma, ACTH-producing adenoma, and 
hyperparathyroidism. The neuroendocrine cervical carcinoma showed a loss of 
the wild-type allele in tumor-derived DNA. Furthermore, the p27 IHC analysis 
showed negative immunoreactivity of p27 protein in the particular tumor tissue. 
These results strengthened the tumor suppressor role of the CDKN1B/p27Kip1 in 
endocrine neoplasia (Pellegata et al. 2006). The previous knock-out mouse models 
had suggested the role of CDKN1B/p27Kip1 in endocrine neoplasia (Fero et al. 1996; 
Kiyokawa et al. 1996; Nakayama et al. 1996), but our finding confirmed the role of 
CDKN1B/p27Kip1 in human endocrine neoplasia.  
 
So far, five mutation-positive index cases have been identified among 
approximately 340 studied cases (study IV; Agarwal et al. 2009; Igreja et al. 2009; 
Owens et al. 2009; Ozawa et al. 2007). Two of these cases are familial and three 
apparently sporadic. These results indicate that CDKN1B/p27Kip1 mutations occur 
at a low frequency in the suspected MEN1 patients without MEN1 mutation. 
 
In study IV, none of the familial and sporadic pituitary adenoma patients 
harbored potentially pathogenic CDKN1B/p27Kip1 mutations. This is in 
concordance with the previous negative mutation screenings of CDKN1B/p27Kip1 
in the pituitary adenomas (e.g. Ikeda et al. 1997; Tanaka et al. 1997). Thus, it seems 
that CDKN1B/p27Kip1 mutations are rare or non-existent in the familial or sporadic 
pituitary adenoma patients.  
 
Hyperparathyroidism has been diagnosed in all CDKN1B/p27Kip1 mutation-
positive index cases (study IV; Agarwal et  al. 2009; Pellegata et  al. 2006). In a 
recent study, potentially pathogenic CDKN1B/p27Kip1 mutations were not detected 
in presumably familial hyperparathyroidism patients (Vierimaa et  al. 2009). 
Furthermore, screening of somatic CDKN1B/p27Kip1 mutations in sporadic 
secondary/tertiary hyperparathyroidism was also negative (Lauter and Arnold 
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2008). These results indicate that CDKN1B/p27Kip1 does not have a major 
contribution to familial or sporadic hyperparathyroidism. 
 
The rarity of mutations among the suspected MEN1 patients and the variable 
phenotype of CDKN1B/p27Kip1 mutation carriers complicate the identification of 
these patients. Nonetheless, the clinicians should be aware that at least some of 




7. CONCLUSIONS AND FUTURE PROSPECTS 
 
This work studied the role of AIP and CDKN1B/p27Kip1 in endocrine neoplasia. 
Conclusions of this work are summarized as follows: 
 
I) Germ-line AIP mutations are found at low frequencies (0.8-7.4%) in diverse 
settings of the pituitary adenoma patients.  Most of the AIP mutation-positive 
patients have GH-producing adenomas. Often these patients are young and they 
may not display a family history of pituitary adenomas. With further 
optimization, the AIP IHC could be used as a pre-screening tool for the 
identification of potential PAP patients.  
 
II) Somatic mutations of AIP are rare or do not exist in sporadic endocrine 
tumors.  
 
III) AIP is unlikely to be a predisposing gene for familial NMTC. 
 
IV) The second CDKN1B/p27Kip1 mutation was identified in suspected MEN1 
patients without MEN1 mutations.  
 
Identification of the predisposing genes for familial syndromes has raised general 
awareness. The recognition of the mutation-positive families enables regular 
follow-up of the mutation carriers followed by early diagnosis. With the 
appropriate treatments, the morbidity of these patients can be diminished. This 
way the quality of the patient's life can be improved and premature death can 
even be avoided. In addition, the family members without mutation can be 
relieved from the unnecessary follow-ups.  
 
So far, mutations in MEN1, PRKAR1A, CDKN1B/p27Kip1, and AIP are known to 
predispose to endocrine neoplasia with pituitary adenomas. However, the 
majority of the familial, isolated pituitary adenomas do not harbor mutations in 
these genes and thus new predisposing gene(s) remain to be identified. 
 
The diagnosis of gigantism is unambiguous whereas acromegaly develops 
insidiously often leading to delayed diagnosis. For this reason, the identification 
of the AIP mutation carriers is important. This is challenging due to the rarity of 
AIP mutations in sporadic cases and often the lack of family history of pituitary 
adenomas. However, the AIP mutation screening should be considered for 
patients with familial pituitary adenomas, particularly if affected patients have 
GH-producing adenomas. Furthermore, the contribution of AIP mutations 
should be suspected if a seemingly sporadic patient is diagnosed with GH-




For the AIP mutation carriers it seems reasonable to offer a non-invasive clinical 
follow-up, such as a biochemical screening for markers (e.g. hormones) from the 
blood and possibly the pituitary MRI scanning. For instance, in the MEN1 
mutation-positive patients the early marks of neoplasia can be detected 
biochemically on average 10 years prior to the clinically evident disease 
(Lairmore et al. 2004).  
 
Clinical follow-up of the CDKN1B/p27Kip1 mutation carriers is recommended. 
However, the mutation screening of CDKN1B/p27Kip1 gene seems unreasonable 
due to the rarity of mutations. Nonetheless, the clinicians should be aware that 
small portion of suspected MEN1 patients without MEN1 gene  mutations  may  
have CDKN1B/p27Kip1 gene mutation. 
 
During the last decades, factors contributing to the pituitary tumorigenesis have 
been identified but the underlying processes are largely unknown. To gain 
insight into this issue, rigorous in vitro and in vivo studies are needed. The lack of 
functional human pituitary cell line requires the use of animal cell lines for these 
experiments. Currently, there is a great interest towards the possible tumor 
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